COVID-19
Eli Lilly’s COVID-19 treatment combination 87% effective in Phase III trial
March 11, 2021COVID-19, Eli Lilly, covid-19 treatment
Eli Lilly has shown positive results in its Phase III combination drug trial, which reduced hospitalisations and deaths related to …
Pharmafile.com’s weekly COVID-19 news round-up
March 10, 2021Research and Development COVID, COVID Vaccine, COVID-19, coronavirus, covid round-up
The past week has continued to see positive COVID-19 news; CytoDyn’s treatment for patients with severe symptoms of the virus …
Valo and ImmunoScape collaboration identifies immunogenic peptides for pan-coronavirus vaccine
March 9, 2021Manufacturing and Production COVID-19, Valo Therapeutics, immunoscape, vaccines
Immunotherapy platform developer Valo Therapeutics has successfully completed a collaboration with the biotechnology company ImmunoScape to identify immunogenic peptides for …
CHMP recommends Lilly’s bamlanivimab for COVID-19 patients
March 8, 2021Sales and Marketing COVID-19, EMA, Eli Lilly
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for Eli Lilly’s bamlanivimab …
Pharmafile.com’s top 10 news stories of the week
March 5, 2021Medical Communications COVID, COVID-19, COVID-19 vaccine, news roundup, pharma news, roundup
The last week has seen its fair share of COVID-19 vaccine developments; Bharat Biotech’s candidate was found to be 81% …
Novartis signs agreement to manufacture CureVac’s COVID-19 vaccine
March 5, 2021Medical Communications COVID-19, CureVac, Novartis, vaccines
CureVac and Novartis have signed an initial agreement for the manufacturing of CureVac’s COVID-19 vaccine candidate, CVnCoV. Preparations for the …
UK government invests £5m in COVID-19 mRNA vaccine library
March 5, 2021Medical Communications COVID-19, CPI, government, vaccines
The Centre for Process Innovation (CPI) has received a £5 million investment from the UK government, to support the development …
Bharat Biotech’s COVAXIN jab 81% effective in Phase III trial
March 4, 2021Bharat Biotech, COVID-19, COVID-19 vaccine, Vaccine, bharat
Bharat Biotech’s COVID-19 vaccine candidate has shown an interim efficacy of 81% in a Phase III trial, the company announced …
Single Pfizer or AstraZeneca vaccine dose drastically reduces COVID-19 hospitalisations in over-80s
March 2, 2021Manufacturing and Production AstraZeneca, COVID-19, COVID-19 vaccine, Pfizer, Vaccine
A single dose of the Oxford-AstraZeneca or the Pfizer-BioNTech vaccine reduces UK hospitalisations in over-80s by 80%, a Public Health …
CN Bio receives UK government grant to develop single and multi-organ models for COVID-19 research
March 2, 2021Manufacturing and Production CN Bio, COVID-19
CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), has received a grant from innovation agency Innovate …
FDA approves Johnson & Johnson’s COVID-19 vaccine for emergency use
March 1, 2021Sales and Marketing COVID-19, Janssen, Johnson & Johnson, vaccines
The FDA has issued emergency use authorisation for Johnson & Johnson’s one-shot COVID-19 vaccine, approving the jab for use in …
MAPs during a global pandemic
February 26, 2021Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, MAPS
Early and managed access programmes provide opportunities for patients to get the treatments they need faster – but the COVID-19 …
GSK’s Phase II otilimab study on COVID-19 patients promising for over-70s
February 26, 2021Medical Communications COVID-19, GSK, coronavirus, covid-19 treatment, otilimab
GlaxoSmithKline’s (GSK) Phase II OSCAR study of their otilimab antibody’s effect on COVID-19 patients has shown promising results in older …
How COVID-19 has changed pharmacovigilance
February 26, 2021Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, pharmacovigilance
The race to provide vaccines and treatments for coronavirus has seen a number of COVID-19 drugs reach the market in …
RedHill Biopharma to expand COVID-19 opaganib trial to US
February 24, 2021Research and Development COVID-19, RedHill Biopharma
RedHill Biopharma has announced its plans to expand the company’s global Phase II/III study of opaganib in patients with severe …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
